Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.
Short position
Imugene (ASX:IMU) has 0.34% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,858,764 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.30 percentage points. Its highest recorded short interest was 8.10% in August 2023. IMU is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4IMU community
Research Threads
Bull, bear, catalyst, and news-reaction posts tied directly to IMU.
Start the first IMU research thread
Anchor the conversation with a thesis, a catalyst, or a question worth debating.